GGrantIndex
Sort

78,016 grants matching breast cancer

Sulfur(VI) Fluoride Exchange (SuFEx): new developments and biological applications

$443,750
K Barry Sharpless · Scripps Research Institute, The · R01 · FY2020 · GM

Sulfur(VI) Fluoride Exchange (SuFEx): new developments and biological applications

$443,750
K Barry Sharpless · Scripps Research Institute, The · R01 · FY2022 · GM

Sulfur(VI) Fluoride Exchange (SuFEx): new developments and biological applications

$443,750
K Barry Sharpless · Scripps Research Institute, The · R01 · FY2023 · GM

Sulfur(VI) Fluoride Exchange (SuFEx): new developments and biological applications

$443,750
K Barry Sharpless · Scripps Research Institute, The · R01 · FY2021 · GM

Human Breast Cancer Stem Cell Surrogates

$443,749
Wendy A Woodward · University Of Tx Md Anderson Can Ctr · R01 · FY2012 · CA

Patient Navigation for Cervical Cancer in Appalachia

$443,742
Mark B. Dignan · University Of Kentucky · R01 · FY2009 · CA

KanSurvive: Testing a model for improving cancer survivorship care in rural practice

$443,740
Jennifer Rose Klemp · University Of Kansas Medical Center · R01 · FY2022 · CA

A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer

$443,721
Qing Zhang · Ut Southwestern Medical Center · R01 · FY2023 · CA

MicroRNA profiles of TN breast cancer to define subgroups and targets for therapy

$443,720
Kay Huebner · Ohio State University · U01 · FY2012 · CA

NESTED NANOTHERAPEUTICS FOR DRUG SYNERGY ENHANCEMENT IN BREAST CANCER THERAPY

$443,674
The Methodist Hospital Research Institute · · FY2011 · Department of Defense

Proteomics Biomarkers Development Laboratory

$443,657
Samir M Hanash · Fred Hutchinson Cancer Research Center · U01 · FY2009 · CA

Targeting Chemotherapy-induced Breast Cancer Stemness

$443,640
Shizhen Emily Wang · University Of California, San Diego · R01 · FY2021 · CA

Combined NGS tumor-based detection of germline Lynch syndrome mutations and prognostic classification of endometrial cancers

$443,629
Paul Joseph Goodfellow · Ohio State University · R01 · FY2022 · CA

Defining BRCA replication dysfunction in therapy response

$443,626
Sharon B Cantor · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · CA

Cancer in adults following in utero and early life exposure to arsenic

$443,622
Craig M Steinmaus · University Of California Berkeley · R01 · FY2016 · ES

Novel L-threo-sphinganines for ceramides-based cancer therapy

$443,579
Barry J Maurer · Texas Tech University Health Scis Center · R15 · FY2012 · CA

Immobilized Drug Transporters

$443,566
Irving William Wainer · National Institute On Aging · ZIA · FY2011 · AG

Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation

$443,556
Xinna Zhang · Indiana University Indianapolis · R01 · FY2024 · CA

IMRT in the Treatment of Node-Positive Breast Cancer

$443,551
Lori J Pierce · University Of Michigan At Ann Arbor · R01 · FY2006 · CA

Computer-aided tool for diagnostic breast ultrasound

$443,533
Michael Galperin · Almen Laboratories, Inc. · R44 · FY2008 · CA

Scott and White Community Clinical Oncology Program

$443,531
Scott And White Memorial Hospital · U10 · FY2004 · CA

Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy

$443,515
Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Mechano sensitive peptide aggregates for targeted therapy

$443,477
Mathumai Kanapathipillai · University Of Michigan At Dearborn · R15 · FY2020 · GM

Development and application of asymmetric-flow field-flow (AF4) technology in fractionation and characterization of exosome subpopulations and novel nanoveiscles in pancreatic cancer model

$443,445
David Charles Lyden · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA

Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca

$443,410
Neal Rosen · Sloan-Kettering Inst Can Research · P01 · FY2012 · CA